Chris Hollowood, Freeline chairman (Syncona)
June 30, 2020 07:21 AM EDT
Financing
Cell/Gene Tx

Free­line nabs $120M, eyes IPO as its gene ther­a­py comes in­to fo­cus

Jason Mast

Editor

Free­line Ther­a­peu­tics has land­ed an­oth­er mega-round to back its gene ther­a­py ef­forts and, on the same morn­ing of the an­nounce­ment, in­di­cat­ed that they could yet …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times